Noticias de Genzyme

May 7, 2008	Preliminary Results from Phase 2 Genzyme Study
April 25, 2008	FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen
April 23, 2008	Genzyme Reports Strong First-Quarter Growth
April 22, 2008	Genzyme to Build New R&D Center in Beijing
April 21, 2008	Genzyme Provides Update on Myozyme® Manufacturing
April 14, 2008	Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy
March 19, 2008	Genzyme Withdraws Bioenvision’s European Filing of Evoltra® in Elderly AML Patients
March 10, 2008	Genzyme Announces Presentation of New Positive Data on Carticel®
March 6, 2008	Genzyme Launches Renvela® in the U.S. for Dialysis Patients
February 13, 2008	Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year
February 1, 2008	University of Massachusetts and Genzyme Launch Genzyme/UMass Scholars Program
February 1, 2008	Genzyme and Isis Announce Hart-Scott-Rodino Approval Of Collaboration
January 15, 2008	Genzyme Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Lung Cancer Diagnostic
January 8, 2008	Genzyme Reports 21 Percent Increase in Fourth-Quarter Revenue
January 7, 2008	Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
December 19, 2007	Genzyme Receives European CE Mark for Single-Treatment Synvisc-One™
December 17, 2007	Genzyme Announces FDA Approval of Thyrogen® For Use In Thyroid Cancer Ablation
December 13, 2007	Genzyme Study of Myozyme® for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
December 5, 2007	Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML
December 4, 2007	National Cancer Institute Study to Determine the Optimal Time for CLL Patients to Begin Treatment
November 13, 2007	Genzyme Receives FDA Response Letter on Synvisc-One™
October 29, 2007	Epicel™ Wins Marketing Approval for Severe Burn Victims
October 25, 2007	Genzyme and Sunway to Collaborate on Gene Therapy Program in China
October 24, 2007	Genzyme Reports Strong Earnings Growth in Third Quarter
October 23, 2007	Genzyme Launches Cholestagel® in Europe
October 22, 2007	Bioenvision Shareholders Approve Acquisition by Genzyme Corporation
October 22, 2007	FDA Approves Genzyme's Renvela™ for Dialysis Patients
October 16, 2007	Genzyme Statement Regarding Results of FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
October 15, 2007	Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis
October 12, 2007	Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
October 12, 2007	Genzyme Recognized by Scientists as a Top Employer
October 10, 2007	Delaware Court Approves Bioenvision, Genzyme Joint Petition
October 10, 2007	Bioenvision and Genzyme File Petition in Delaware Court
October 4, 2007	Genzyme Receives Approval to Market Elaprase® in Japan
September 27, 2007	Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
September 26, 2007	Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
September 20, 2007	FDA Approves Expanded Labeling for Campath® to Include First-line Treatment for Leading Form of Adult Leukemia
September 18, 2007	Genzyme Begins Major Expansion of Boston Manufacturing Facility
August 29, 2007	Genzyme Announces Publication of DCOR Study in Kidney International
August 9, 2007	Genzyme Announces Settlement of Lawsuit Concerning Consolidation of Tracking Stocks
August 2, 2007	Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
July 25, 2007	Genzyme Reports Significant Earnings Growth in Second Quarter
July 23, 2007	Oswaldo Cruz Foundation and Genzyme Corporation Form Collaboration To Advance New Drugs for Neglected Diseases
July 19, 2007	Genzyme Announces Phase 3 Trial of Mozobil in non-Hodgkin’s Lymphoma Meets Primary Endpoint
July 16, 2007	Genzyme Announces Positive Results from Carticel® Study at Major Sports Medicine Meeting
July 10, 2007	Genzyme Completes Tender Offer to Acquire Bioenvision, Inc.
July 6, 2007	Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
July 5, 2007	Genzyme Announces Results of Clinical Trial of Hylastan
July 2, 2007	Genzyme Extends Tender Offer to Acquire Bioenvision, Inc.
June 27, 2007	Genzyme Corporation Moves Closer to Acquiring Bioenvision, Inc.
June 25, 2007	Genzyme Receives FDA Approval for New Labeling for Carticel®
June 21, 2007	Ceregene and Genzyme Announce Partnership for the Development and Commercialization of CERE-120 for Parkinson’s Disease
June 20, 2007	Genzyme Files for Approval of Single-Treatment Synvisc-One™
June 18, 2007	Genzyme Awarded U.S. National Medal of Technology
June 18, 2007	Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
June 7, 2007	Genzyme to Build New Biomanufacturing Plant to Support Growth of Thymoglobulin®
May 29, 2007	Genzyme Corporation to Acquire Bioenvision, Inc.
May 29 2007	Genzyme Announces $1.5 Billion Share Repurchase Authorization
May 22 2007	Genzyme Announces Publication in PNAS Describing Novel Gene Therapy Approach for Niemann Pick Disease
May 16 2007	Genzyme Announces Positive Initial Observations in Trial Evaluating Novel Oral Treatment for Gaucher Disease

Términos y Condiciones de Uso | Política de Privacidad | © 2008 Genzyme Corporation. Todos los Derechos Reservados.